Tempus AI, Inc. (TEM)
Here's How Tempus AI Is Tapping the Imagining Space
TEM expands into radiology via Median partnership, adding AI lung screening to Pixel as FDA clearance and past deals boost imaging push.
AI-Driven Innovation Accelerates Tempus AI's Expansion Across MedTech
TEM rolls out new AI tools across oncology, cardiology and mental health, accelerating its push to reshape MedTech innovation.
Is TEM Stock A Buy At $60?
Tempus AI (NASDAQ: TEM) trades at a premium by traditional metrics, remains unprofitable on a GAAP basis, and has spent the past week benefiting from strong analyst optimism. So why might the stock still appear attractive at $60?
Unlocking Q4 Potential of Tempus (TEM): Exploring Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Tempus (TEM) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week's Earnings
Tempus AI, Inc. (NASDAQ:TEM) shares are climbing today after the company unveiled a new AI-powered cancer diagnostic algorithm, building momentum ahead of its Q4 2025 earnings report scheduled for February 24, 2026 after market close.
Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
TEM heads into Q4 earnings with expected 82.8% revenue growth, rising oncology momentum and a premium valuation clouding near-term upside.
Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel
TEM teams with Median to add FDA-cleared eyonis LCS to Pixel, boosting AI lung cancer screening and expanding its imaging portfolio.
Should You Buy, Hold or Sell Tempus AI Stock Pre-Q4 Earnings Release?
In preliminary, unaudited financial results, TEM posts 83% revenue growth and record data sales in 2025, but valuation and ongoing GAAP losses cloud the outlook before Q4 earnings.
TEM vs. DOCS: Which Medical-Tech Stock Looks Promising Amid AI Boom?
AI momentum is reshaping med-tech, with Tempus AI scaling diagnostics and Doximity leveraging platform-wide AI, strong margins, and cash flow to gain an edge.
How TEM Is Capitalizing on AI-Driven Pathology Market Growth
Tempus AI boosts AI pathology reach by acquiring Paige and launching Paige Predict to deliver biomarker insights across 16 cancer types.
Tempus AI: Staying Bullish On Leading Healthcare AI Play
Tempus AI (TEM) remains a resilient healthcare AI leader, with proprietary data driving traction and a clear buy opportunity amid recent volatility. TEM reported preliminary 2025 revenue of ~$1.27B (+30% organic growth) and >$1.1B total contract value, supporting a robust multi-year growth runway. 2026 guidance calls for 25% revenue growth to $1.59B and adjusted EBITDA expansion to ~$65M, with management reinvesting two-thirds of incremental profit.
Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention
TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.
